medigraphic.com
ISSN 1029-3019 (Electronic)

2014, Number 05

<< Back Next >>

MediSan 2014; 18 (05)

Complications of intravitreal triamcinolone in patients with macular disorders secondary to neovascularization

Moya CM, González DRE, Sánchez BFA, Cobas GR, Boudet DO

Language: Spanish
References: 20
Page: 644-651
PDF size: 55.33 Kb.


ABSTRACT

A descriptive and retrospective study in 109 patients with macular diseases, assisted in the Ophthalmological Center of "Dr. Juan Bruno Zayas Alfonso" Teaching General Hospital in Santiago de Cuba was carried out from September, 2011 to July, 2012, to whom 4 mg of triamcinolone intravitreal (via pars plana) were administered in unique dose, in order to describe the complications presented after the treatment. Female sex (64.3%), the age group 65-84 years (49.5%) and macular degeneration associated with age (wet) as ophthalmological history (76.1%) prevailed in the case material. Among the most frequent complications there were: secondary ocular hypertension (13.7%) and cataract (11.9%).


REFERENCES

  1. Garg A. Textbook of Ocular Therapeutics. 2 ed. New Delhi: Editorial Jaypee. 2003. p.7-67.

  2. Gómez Ulla F, Basauri E, Arias L, Martínez Sanz F. Manejo de las inyecciones intravítreas. Arch Soc Esp Oftalmol. 2009[citado 8 Dic 2013];84(8).

  3. Ramos López M, Arencibia Gonzáles D, Hernández Silva JR. Factor de crecimiento vascular endotelial y sus inhibidores en la neovascularización coroidea. En: Ríos Torres M, Capote Cabrera A, Padilla González CM, Eguía Martínez F, Hernández Silva JR. Oftalmología. Criterios y tendencias actuales. La Habana: Editorial Ciencias Médicas;2009. p. 472-83.

  4. Alfaro Virgil D, Ligget PE, Mieler W. Age-related macular degeneration. Intravitreal triamcinolone for choroidal neovascularization. Philadelphia: Lippincott William Wilkins;2003. p. 296.

  5. Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye (Lond). 2009;23(12):2215–22.

  6. Lai CC, Wang NK, Wu WC, Yeung L, Hwang YS, Chen Kj, et al. The long-term anatomical and visual effect of intravitreal triamcinolone injection during vitrectomy for the treatment of idiopathic macular epiretinal membrane. Cutan Ocul Toxicol. 2011;30(4):292-7.

  7. Parke DW, Sisk RA, Houston SK, Murray TG. Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification. Clin Ophthalmol. 2012;6: 925–31.

  8. Valverde Megías A, Arriola Villalobos P, Reche Frutos J, Donate López J, Calvo González C, García Feijoo J. Ranibizumab (Lucentis®) intravítreo en el tratamiento de membrana neovascular coroidea secundaria a coroidopatía punctata interna. Arch Soc Esp Oftalmol. 2010 [citado 8 Dic 2013];85(4).

  9. Oliva G, Navarro L. Degeneración macular asociada a la edad: estrategias actuales en el tratamiento. Informes de Evaluación de Tecnologías Sanitarias AATRM. 2007. [citado 8 Dic 2013].

  10. Flaxel C, Schain MB, Hamon S, Francis PH. Tratamiento de la degeneración macular asociada con la edad. Retina. 2012;32:417-23.

  11. Wu L, Evans T. Cambios inmediatos en la presión intraocular después de una inyección intravítrea de 2,5 mg de bevacizumab. Arch Soc Esp Oftalmol. 2010;85(11):364-9.

  12. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112(4):593-8.

  13. Arévalo JF. ¿Quién debe aplicar las inyecciones intravítreas? Arch Soc Esp Oftalmol. 2011[citado 8 Dic 2013];86(3).

  14. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005;19(2):122-7. .

  15. Chew EY, Glassman AR, Beck RW, Bressler NM, Fish GE, Ferris FL, et al. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina. 2011;31(2):284–9.

  16. Baheti U, Siddique SS, Foster CS. Cataract surgery in patients with history of uveitis. Saudi J Ophthalmol. 2012;26(1):55–60.

  17. Gillies MC, Islam FM, Larsson J, Pasadhika S, Gaston C, Zhu M, et al. Triamcinoloneinduced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical Experimental Ophthalmology. 2010;38(6):605–12.

  18. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-82.

  19. Alonso Herreros JM. The pharmacist's role in choosing health material: intravitreal triamcinolone. Farm Hosp. 2011;35(3):156-7.

  20. Sugimoto M, Kondo M, Horiguchi M. Uniform suspension of the clustered triamcinolone acetonide particle. J Ophthalmology. 2013;2013:8.




2020     |     www.medigraphic.com